Variations in Insurance Coverage for Autologous Bone Marrow Transplantation for Breast Cancer
To the Editor: In concluding that the current process for making decisions about coverage of high-dose chemotherapy for breast cancer is “arbitrary and capricious,” Drs. Peters and Rogers (Feb. 17 issue) 1 assume that . . . only insurers have a financial interest in making determinations about cover...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 1994-08, Vol.331 (5), p.329-331 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 331 |
|---|---|
| container_issue | 5 |
| container_start_page | 329 |
| container_title | The New England journal of medicine |
| container_volume | 331 |
| creator | Krause, Kenneth J Cutler, Charles M Udvarhelyi, I. Steven Winkenwerder, William Erban, John K Templeton, Katherine M Wingard, John R Khanna, Vikram Peters, William P Rogers, Mark C |
| description | To the Editor:
In concluding that the current process for making decisions about coverage of high-dose chemotherapy for breast cancer is “arbitrary and capricious,” Drs. Peters and Rogers (Feb. 17 issue)
1
assume that . . . only insurers have a financial interest in making determinations about coverage. At the commonly quoted price of $150,000 per course of treatment, however, treatment of the 533 women in their analysis represents an annual income of $20 million to their institution alone. Institutions, providers, and suppliers all benefit substantially from insurance coverage for this treatment.
Though the authors indicate otherwise, publication of their article . . . |
| doi_str_mv | 10.1056/NEJM199408043310514 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76574290</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76572136</sourcerecordid><originalsourceid>FETCH-LOGICAL-c436t-8313f2e897516a92c44c0ad354155e1c54cba38091ff8ac7e96b2fc2d04ba2993</originalsourceid><addsrcrecordid>eNqNkE1Lw0AQhhdRaq3-AhH25EWi-zGbZI9tqFqxeqneJGy2m5LSZOtuovjv3X7gScS5DMw88zC8CJ1Tck2JiG-exg9TKiWQlADnYUThAPWp4DwCIPEh6hPC0ggSyY_RifdLEoqC7KFeShgDkH309qpcpdrKNh5XDZ40vnOq0QZn9sM4tTC4tA4Pu9au7MJ2Ho9sY_BUOWc_8Sygfr1STbs1bNGRM8q3ONtI3Ck6KtXKm7N9H6CX2_Esu48en-8m2fAx0sDjNko55SUzqUwEjZVkGkATNecCqBCGagG6UDwlkpZlqnRiZFywUrM5gUIxKfkAXe68a2ffO-PbvK68NqvwmglP50ksEmCS_AtklMcB5DtQO-u9M2W-dlWt3FdOSb5JP_8l_XB1sdd3RW3mPzf7uMP-areva583Zln_afsGFVyL2w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76572136</pqid></control><display><type>article</type><title>Variations in Insurance Coverage for Autologous Bone Marrow Transplantation for Breast Cancer</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>New England Journal of Medicine</source><creator>Krause, Kenneth J ; Cutler, Charles M ; Udvarhelyi, I. Steven ; Winkenwerder, William ; Erban, John K ; Templeton, Katherine M ; Wingard, John R ; Khanna, Vikram ; Peters, William P ; Rogers, Mark C</creator><creatorcontrib>Krause, Kenneth J ; Cutler, Charles M ; Udvarhelyi, I. Steven ; Winkenwerder, William ; Erban, John K ; Templeton, Katherine M ; Wingard, John R ; Khanna, Vikram ; Peters, William P ; Rogers, Mark C</creatorcontrib><description>To the Editor:
In concluding that the current process for making decisions about coverage of high-dose chemotherapy for breast cancer is “arbitrary and capricious,” Drs. Peters and Rogers (Feb. 17 issue)
1
assume that . . . only insurers have a financial interest in making determinations about coverage. At the commonly quoted price of $150,000 per course of treatment, however, treatment of the 533 women in their analysis represents an annual income of $20 million to their institution alone. Institutions, providers, and suppliers all benefit substantially from insurance coverage for this treatment.
Though the authors indicate otherwise, publication of their article . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJM199408043310514</identifier><identifier>PMID: 8022449</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Antineoplastic Agents - therapeutic use ; Bone Marrow Transplantation - economics ; Breast Neoplasms - drug therapy ; Breast Neoplasms - therapy ; Eligibility Determination ; Female ; Humans ; Insurance Claim Review ; Insurance, Health</subject><ispartof>The New England journal of medicine, 1994-08, Vol.331 (5), p.329-331</ispartof><rights>Copyright © 1994 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c436t-8313f2e897516a92c44c0ad354155e1c54cba38091ff8ac7e96b2fc2d04ba2993</citedby><cites>FETCH-LOGICAL-c436t-8313f2e897516a92c44c0ad354155e1c54cba38091ff8ac7e96b2fc2d04ba2993</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJM199408043310514$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJM199408043310514$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8022449$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Krause, Kenneth J</creatorcontrib><creatorcontrib>Cutler, Charles M</creatorcontrib><creatorcontrib>Udvarhelyi, I. Steven</creatorcontrib><creatorcontrib>Winkenwerder, William</creatorcontrib><creatorcontrib>Erban, John K</creatorcontrib><creatorcontrib>Templeton, Katherine M</creatorcontrib><creatorcontrib>Wingard, John R</creatorcontrib><creatorcontrib>Khanna, Vikram</creatorcontrib><creatorcontrib>Peters, William P</creatorcontrib><creatorcontrib>Rogers, Mark C</creatorcontrib><title>Variations in Insurance Coverage for Autologous Bone Marrow Transplantation for Breast Cancer</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>To the Editor:
In concluding that the current process for making decisions about coverage of high-dose chemotherapy for breast cancer is “arbitrary and capricious,” Drs. Peters and Rogers (Feb. 17 issue)
1
assume that . . . only insurers have a financial interest in making determinations about coverage. At the commonly quoted price of $150,000 per course of treatment, however, treatment of the 533 women in their analysis represents an annual income of $20 million to their institution alone. Institutions, providers, and suppliers all benefit substantially from insurance coverage for this treatment.
Though the authors indicate otherwise, publication of their article . . .</description><subject>Antineoplastic Agents - therapeutic use</subject><subject>Bone Marrow Transplantation - economics</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - therapy</subject><subject>Eligibility Determination</subject><subject>Female</subject><subject>Humans</subject><subject>Insurance Claim Review</subject><subject>Insurance, Health</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkE1Lw0AQhhdRaq3-AhH25EWi-zGbZI9tqFqxeqneJGy2m5LSZOtuovjv3X7gScS5DMw88zC8CJ1Tck2JiG-exg9TKiWQlADnYUThAPWp4DwCIPEh6hPC0ggSyY_RifdLEoqC7KFeShgDkH309qpcpdrKNh5XDZ40vnOq0QZn9sM4tTC4tA4Pu9au7MJ2Ho9sY_BUOWc_8Sygfr1STbs1bNGRM8q3ONtI3Ck6KtXKm7N9H6CX2_Esu48en-8m2fAx0sDjNko55SUzqUwEjZVkGkATNecCqBCGagG6UDwlkpZlqnRiZFywUrM5gUIxKfkAXe68a2ffO-PbvK68NqvwmglP50ksEmCS_AtklMcB5DtQO-u9M2W-dlWt3FdOSb5JP_8l_XB1sdd3RW3mPzf7uMP-areva583Zln_afsGFVyL2w</recordid><startdate>19940804</startdate><enddate>19940804</enddate><creator>Krause, Kenneth J</creator><creator>Cutler, Charles M</creator><creator>Udvarhelyi, I. Steven</creator><creator>Winkenwerder, William</creator><creator>Erban, John K</creator><creator>Templeton, Katherine M</creator><creator>Wingard, John R</creator><creator>Khanna, Vikram</creator><creator>Peters, William P</creator><creator>Rogers, Mark C</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19940804</creationdate><title>Variations in Insurance Coverage for Autologous Bone Marrow Transplantation for Breast Cancer</title><author>Krause, Kenneth J ; Cutler, Charles M ; Udvarhelyi, I. Steven ; Winkenwerder, William ; Erban, John K ; Templeton, Katherine M ; Wingard, John R ; Khanna, Vikram ; Peters, William P ; Rogers, Mark C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c436t-8313f2e897516a92c44c0ad354155e1c54cba38091ff8ac7e96b2fc2d04ba2993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Antineoplastic Agents - therapeutic use</topic><topic>Bone Marrow Transplantation - economics</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - therapy</topic><topic>Eligibility Determination</topic><topic>Female</topic><topic>Humans</topic><topic>Insurance Claim Review</topic><topic>Insurance, Health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Krause, Kenneth J</creatorcontrib><creatorcontrib>Cutler, Charles M</creatorcontrib><creatorcontrib>Udvarhelyi, I. Steven</creatorcontrib><creatorcontrib>Winkenwerder, William</creatorcontrib><creatorcontrib>Erban, John K</creatorcontrib><creatorcontrib>Templeton, Katherine M</creatorcontrib><creatorcontrib>Wingard, John R</creatorcontrib><creatorcontrib>Khanna, Vikram</creatorcontrib><creatorcontrib>Peters, William P</creatorcontrib><creatorcontrib>Rogers, Mark C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Krause, Kenneth J</au><au>Cutler, Charles M</au><au>Udvarhelyi, I. Steven</au><au>Winkenwerder, William</au><au>Erban, John K</au><au>Templeton, Katherine M</au><au>Wingard, John R</au><au>Khanna, Vikram</au><au>Peters, William P</au><au>Rogers, Mark C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Variations in Insurance Coverage for Autologous Bone Marrow Transplantation for Breast Cancer</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>1994-08-04</date><risdate>1994</risdate><volume>331</volume><issue>5</issue><spage>329</spage><epage>331</epage><pages>329-331</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>To the Editor:
In concluding that the current process for making decisions about coverage of high-dose chemotherapy for breast cancer is “arbitrary and capricious,” Drs. Peters and Rogers (Feb. 17 issue)
1
assume that . . . only insurers have a financial interest in making determinations about coverage. At the commonly quoted price of $150,000 per course of treatment, however, treatment of the 533 women in their analysis represents an annual income of $20 million to their institution alone. Institutions, providers, and suppliers all benefit substantially from insurance coverage for this treatment.
Though the authors indicate otherwise, publication of their article . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>8022449</pmid><doi>10.1056/NEJM199408043310514</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 1994-08, Vol.331 (5), p.329-331 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76574290 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; New England Journal of Medicine |
| subjects | Antineoplastic Agents - therapeutic use Bone Marrow Transplantation - economics Breast Neoplasms - drug therapy Breast Neoplasms - therapy Eligibility Determination Female Humans Insurance Claim Review Insurance, Health |
| title | Variations in Insurance Coverage for Autologous Bone Marrow Transplantation for Breast Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T12%3A39%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Variations%20in%20Insurance%20Coverage%20for%20Autologous%20Bone%20Marrow%20Transplantation%20for%20Breast%20Cancer&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Krause,%20Kenneth%20J&rft.date=1994-08-04&rft.volume=331&rft.issue=5&rft.spage=329&rft.epage=331&rft.pages=329-331&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJM199408043310514&rft_dat=%3Cproquest_cross%3E76572136%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76572136&rft_id=info:pmid/8022449&rfr_iscdi=true |